Dexamethasone improves maximal exercise capacity of individuals susceptible to high altitude pulmonary edema at 4559 m.

We have previously demonstrated that prophylactic intake of dexamethasone improves maximal oxygen uptake (Vo(2)max) in high altitude pulmonary edema (HAPE) susceptible subjects 4 to 6 h after a 2-day climb to 4559 m. However, since with this ascent protocol HAPE usually develops after the first night at 4559 m or later, we hypothesized that a continued dexamethasone prophylaxis would result in an even more pronounced improvement of Vo(2)max after an additional night at high altitude. Vo(2)max of 24 HAPE susceptibles was evaluated on a bicycle ergometer at an altitude of 490 m and at 24 h after rapid ascent to 4559 m. Subjects were divided into two groups: The control group (n=14) performed both tests without dexamethasone, whereas the dexamethasone group (n=10) received dexamethasone 8 mg twice a day (b.i.d), starting 24 h prior to ascent. At 4559 m, Vo(2)max was 61% ± 6% of the baseline value in the control group and 70% ± 9% in the dexamethasone group (p=0.025). Similarly, O(2) pulse (Vo(2)/heart rate) was 68% ± 7% and 77% ± 11% of baseline, respectively (p=0.043). Arterial O(2) saturation at maximal exercise did not differ between groups, whereas at rest it was 83% ± 10% in the control group and 91% ± 4% in the dexamethasone group (p=0.009). Dexamethasone prophylaxis increased Vo(2)max of HAPE-susceptible individuals after the first night at 4559 m without affecting arterial O(2) saturation at maximal exercise. This might be explained by a sustained effect of dexamethasone on maximal cardiac output and pulmonary O(2) diffusion, both resulting in enhanced convectional O(2) transport to the locomotor muscles. © Mary Ann Liebert, Inc.

RCT Entities:   Population Interventions Outcomes